NCT01737827View on ClinicalTrials.gov

Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.

PHASE2TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 25, 2013

Primary Completion Date

April 24, 2023

Study Completion Date

May 24, 2023

Conditions
Advanced Hepatocellular Carcinoma With c-MET Dysregulation
Interventions
DRUG

INC280

INC280 was administered orally on a continuous twice a day (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle. INC280 was initially supplied as hard gelatin capsules and subsequently also as film-coated tablets.

Trial Locations (8)

10330

Novartis Investigative Site, Bangkok

10700

Novartis Investigative Site, Bangkok

40002

Novartis Investigative Site, Khon Kaen

168583

Novartis Investigative Site, Singapore

210002

Novartis Investigative Site, Nanjing

310016

Novartis Investigative Site, Hangzhou

710032

Novartis Investigative Site, Xi’an

Unknown

Novartis Investigative Site, Hong Kong

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY